Registered forecast
35% registered probability event by 2027-02-17 Unresolved
NICE publishes technology appraisal guidance on Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609] on or before 2027-02-17
FF-054 Registered - Registered probability
- 35%
- Event by
- 2027-02-17
- Resolution window
- 2026-10-22 → 2027-02-17
- Target rung
- 5 Guideline
- 6 Regulatory
- 7 Coverage
- Baselines it has to beat
-
- Authority base rate 50%
- Calendar cycle 50%
- Analyst proxy 35%
nextconsensus.com/forecast/ff-054/ registry snapshot 2026-10-21 Share image
NextConsensus registered this probability on 2026-10-21. It is one of 23 registered NICE scheduled-date forecasts.
The proposition
What was claimed
NICE publishes final technology appraisal guidance for the appraisal 'Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments' [ID6609], with a publication date on or before 2027-02-17, the expected publication date shown on its in-development page (https://www.nice.org.uk/guidance/indevelopment/gid-ta11052) on 2026-10-20.
- Authority
- National Institute for Health and Care Excellence (NICE), Technology Appraisal Committee (England)
- Target rungA step on the 12-rung ladder: rungs 1 to 4 are the evidence moving, rungs 5 to 7 are a guideline body, regulator, or payer acting. The ladder, rung by rung
- Rung 7: Payer/coverage action — NCD, LCD, formulary change, step-therapy revision, or access expansion/restriction by CMS, MACs, or major commercial payers.
- Forecast classThe group of like forecasts this one is counted and scored with, such as FDA actions by their goal dates
- NICE guidance by scheduled date
- Scope
- Relapsed or refractory multiple myeloma after 3 or more treatments
The estimate
The number and the baselines it has to beat
The alternatives it was registered against, each with the reasoning that produced it. They were set at registration: how often this kind of decision happens on time, what the calendar alone suggests, and a reading of the same public record without this method. Each one's reasoning shows whether it is a count of past decisions or an estimate.
ESTIMATE FROM THE SHAPE OF THE CLASS, NOT AN ENUMERATED COUNT. The share of NICE technology appraisals published on or before the expected date shown at the cutoff is not yet counted; the calendar's census will count it. Expected dates are revised often, most when a committee meeting does not reach a final recommendation or a company asks for time.
A clock-only model: a single committee meeting on 1 December 2026, 78 days before the expected date, is on schedule if that meeting reaches a final recommendation.
An analyst reading the project page on 2026-10-20 would note a first meeting on a high-cost later-line myeloma medicine, appraised against several active comparators including another BCMA×CD3 bispecific, and would expect draft guidance more often than final draft guidance from that meeting. Estimated by reconstructing that read, not by surveying analysts.
Technology appraisal (NICE): offered on judgment, with no calibration figure until 15 in the class have resolved.
The clock
Dates that constrain the record
- Evidence cutoff
- 2026-10-21
Nothing after this date informed the estimate. - Registered
- 2026-10-21
Frozen and hashed. - Resolution window
- 2026-10-22 → 2027-02-17
When the outcome can be read against the rule. - Event by
- 2027-02-17
The final qualifying action date; the frozen resolution rule defines what counts. Add to calendar
955bbe9e2e4d7a1f28f9a9d278895a3d923a092668490aff384daaaacc285cbe · operator record jc-1792548712971-c4f5f6ca
Around this record
- This kind of deadline
- Check it, follow it
Single-claim evaluation
Waiting on NICE for an asset of your own?
Name the claim, who decides it, and the date your team commits to: a P&T meeting, an HTA submission, a label negotiation, a deal closing. Yours is registered under the same rules as the forecast on this page.
Resolution
The rule that settles the forecast
Resolves YES if the NICE technology appraisal guidance page published from project ID6609 shows a publication date ('Published: <date>') on or before 2027-02-17, whatever the guidance recommends. The adjudicator finds the page from the in-development page above, which links to or redirects to the published guidance, or by searching nice.org.uk for ID6609. Resolves NO if the guidance is published after 2027-02-17, if the expected date is revised and nothing is published by 2027-02-17, if the appraisal is paused or suspended past that date, or if it is terminated. A terminated appraisal stays in the denominator and resolves NO, as registry/CALENDAR.md's rule for this class says. Resolves cancelled_external only if NICE removes the appraisal from its work programme without publishing anything. The frozen date is the one archived at the cutoff; a later revision does not move it. Read no earlier than 2027-02-24. The recommendation itself is a different question and is not scored here. Resolves VOID, with the reason recorded, only if NICE stops publishing technology appraisal guidance pages with publication dates, so that no publication date for this appraisal can be read from nice.org.uk or its successor; while a publication date can be read, the rule stands.
Source the rule names: https://www.nice.org.uk/guidance/indevelopment/gid-ta11052, https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance
Readers: Resolver A, clinical methodology; Resolver B, payer evidence. The same two reader roles are assigned to every forecast registered so far.
What this record will show once it resolves
Beside every result, the count for its class (NICE guidance by scheduled date): registered, resolved, unresolved, and expired. One forecast is one instance, not a rate.
- The finding
- As the rule above reads it: occurred on time, did not occur, or left unscored.
- The readers and their sources
- Two reader roles read the source named above: Resolver A, clinical methodology; Resolver B, payer evidence. Who adjudicated it is named here, with the sources they read when the adjudication lists them. Being named as a reader means applying the frozen rule to the public record; it is not support for the estimate, the method, or NextConsensus.
- The number against its baselines
- 35% beside three baselines, each scored by the same rule (squared error), so a reader can see how the record did against each of them.
Reasoning
What the number rests on
The facts it was built from are below, as they stood at the cutoff, with every source archived; each baseline above carries the reasoning that produced it. The written mechanism and the conditions that would make the proposition ill-posed were frozen with the record and are held in the ledger, which the hash on this page covers.
Frozen covariatesThe facts about the evidence and the authority's process that were frozen with the forecast at its cutoff
The state of the record at the cutoff
Recorded as they stood on 2026-10-21.
- review pathway
- STA Standard ("Process: STA Standard", SRC-001)
- submission type
- New appraisal; company "Regeneron Pharmaceuticals, Inc. (Linvoseltamab)" (SRC-001, SRC-004)
- evidence class
- not applicable — the proposition is a publication date, not an evidence judgement
- pivotal n
- not applicable
- endpoint type
- not applicable — the proposition is a publication date
- approved competitors in class
- Comparator companies participating under confidentiality agreements include Pfizer (elranatamab), Janssen-Cilag (teclistamab, talquetamab, ciltacabtagene autoleucel, daratumumab, bortezomib) and Gilead Sciences (anitocabtagene autoleucel) (SRC-001). Elranatamab and teclistamab are in linvoseltamab's class (BCMA×CD3 bispecific antibodies).
- months since last guideline revision
- not applicable
- panel cycle position
- One committee meeting, on 1 December 2026, 78 days before the expected publication date of 17 February 2027 (SRC-001). SRC-003 lists committee C meeting that day, and the project's enquiry address is TACommC (SRC-001). No draft guidance or second meeting is listed (SRC-001, SRC-002).
- sponsor request status
- None recorded (SRC-001).
- odac referral
- not applicable — NICE committee, not an FDA advisory committee
- sponsor state change
- None recorded (SRC-001).
Sources
Everything the estimate was built from
Each was retrieved on or before the 2026-10-21 cutoff and archived at the digest shown. If a publisher edits a page after the fact, the digest stops matching and the substitution is visible.
-
SRC-001NICE in-development page for ID6609, linvoseltamab for relapsed or refractory multiple myeloma after 3 or more treatments, retrieved at the cutoff. -
SRC-002NICE project documents page for ID6609, retrieved at the cutoff. -
SRC-003NICE technology appraisal committee meetings page, retrieved at the cutoff. -
SRC-004Final stakeholder list (PDF) for the appraisal: names the company and the possible comparator companies.